![]() Research and Business Development Partnerships.The UK was the first country to approve a so-called bivalent vaccine - the Moderna shot - in August, followed then by Switzerland and Australia.Unleashing the next wave of scientific innovations German Health Minister Karl Lauterbach has said that the new vaccines will be available in Germany by next week. While US authorities decided to directly authorize the BA.4/BA.5 adapted shots, the EU has gone instead for the BA.1 vaccines of which large quantities of doses have already been produced. It has since been largely replaced by the BA.5 subvariant. The omicron BA.1 subvariant swept Europe last winter bringing a vast surge in cases. ![]() The US Food and Drug Administration greenlit the BA.4/BA.5 vaccines on Wednesday. A decision on these is expected in the next few weeks, Kyriakides said on Thursday. ![]() Vaccines designed to tackle the BA.4 and BA.5 subvariants are still being reviewed, the EMA said. What about the other omicron subvariants? "We need to be ready to face another winter with COVID-19," she added. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 videoĮuropean Commissioner for Health and Food Safety Stella Kyriakides welcomed the decision as "important to protect Europeans against the likely risk of autumn and winter waves of infections." It also said the studies of the vaccine's effect showed that they "trigger strong immune responses" and that "in particular, they were more effective at triggering immune responses against the BA.1 subvariant than the original vaccines." ![]() "These vaccines are adapted versions of the original vaccines Comirnaty (BioNTech-Pfizer) and Spikevax (Moderna) to target the omicron BA.1 subvariant in addition to the original strain of SARS-CoV-2," the Amsterdam-based regulator said. The EMA recommended their use for anyone aged 12 years and above. The new vaccines function as booster shots for people who have already had a full dose of the original coronavirus vaccine. The European Commission must still give its final approval, but this is expected to be given fairly swiftly. Both also produced vaccines against the first iteration of the virus that were approved by the EMA. The vaccines are the first to target the omicron variant BA.1, as well as being effective against the original strain of the virus. The vaccines were developed by the US-German partnership BioNTech-Pfizer and by the US company Moderna. The EU's drug regulator, the European Medicines Agency (EMA), said on Thursday that it had given the green light to two vaccines that target the omicron variant of COVID-19.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |